Rilpivirine

• Long Acting Cabotegravir plus Rilpivirine in People Living with HIV-1 (PLHIV) Aged ≥ 60 Years for 96 weeks. Ended
  2022-502882-53-00 Phase IV 1 country Fundacion Para La Formacion E Investigacion Sanitaria De La Region De Murcia
• Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 ( ISLEND-… Ended
  2024-514047-28-00 Phase III 4 countries Gilead Sciences Inc.
• PH 3b, CAB + RPV in people with suboptimal response to oral ART (CROWN) Ended
  2024-515070-28-00 Phase III 5 countries Viiv Healthcare UK Limited
• A roll-over study with rilpivirine for human immunodeficiency virus type 1 (HIV-1) infected subjects who participated in rilpivirine pediatr… Ended
  2024-512889-33-00 Phase II 1 country Janssen Sciences Ireland Unlimited Company
• A study to evaluate the efficacy, safety, participant choice and preference of an oral once-daily regimen or a long-acting injectable regim… Ended
  2023-503893-19-00 Phase III 4 countries Viiv Healthcare UK Limited
• Implementation of Out-of-HOspital administration of the Long-Acting combination cabotegravir+rilpivirine as an optional therapy in HIV-Infec… Ended
  2023-503963-41-00 Phase IV 1 country Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocio…
• Phase IV comparative, randomized, open-label pilot study to evaluate the efficacy and safety of a rilpivirine-based antiretroviral treatment… Ended
  2022-503110-23-00 Phase IV 1 country Fundacion Seimc Gesida
• Study on Pharmacokinetics of newly developed ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) Ended
  2024-515487-31-00 Phase IV 5 countries Stichting Radboud universitair medisch centrum

Showing 1–8 of 8 trials